Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +68

Becton, Dickinson: Value Or Overvalued Even Now?

AI-generated analysis

πŸ“‰ Becton, Dickinson (BDX) stock is rated a 'BUY' with a target price under $160/share due to attractive fundamentals.

βš–οΈ The spin-off of the high-margin bioscience segment reduced diversification but left core medtech operations with solid profitability.

πŸ’° Management maintains a robust cash flow generation despite recent structural changes.

πŸ“Š Analysts view BDX's current P/E ratio of 13x as undervalued compared to its conservative potential.

🎯 A fair value target of $215/share is projected for the year 2028E based on value-oriented analysis.

πŸš€ Investors could expect an annualized return exceeding 15% at current price levels.

⚠️ The reduction in diversification warrants a conservative valuation approach, such as a 15x P/E multiple.

πŸ₯ The investment thesis focuses on BDX's solid moat and appealing market share in the healthcare sector.

πŸ” Wolf of Value covers healthcare and healthtech companies with a focus on cheap, qualitative investments.

πŸ’¬ Members gain access to model portfolios, real-time updates, and direct analyst chat features.

⚑ The analyst has over 10 years of experience managing value-oriented portfolios in European and North American markets.

πŸ›‘οΈ Disclaimer states the author is not licensed to give financial advice and investors must do their own due diligence.

Bullish Signals
  • Becton, Dickinson and Company (BDX) is explicitly rated a 'BUY' with a recommended price under $160/share.
  • The company retains core medtech operations that demonstrate solid profitability and robust cash flow generation despite the bioscience segment spin-off.
  • Analyst models BDX as undervalued at its current 13x P/E ratio compared to a fair value target of $215/share by 2028E.
  • Investors are positioned for an annualized return above 15% based on current stock prices and valuation metrics.
  • BDX satisfies key quality and safety criteria, indicating strong operational reliability and market position.
Risk Factors
  • The spin-off of the high-margin bioscience segment has reduced BDX's diversification and margin potential.
  • Despite retaining core operations, the company's valuation is being capped at a conservative 15x P/E multiple instead of the 13x currently observed.
  • Investors must note that past performance is no guarantee of future results and the author explicitly states they are not licensed to give financial advice.
Full Analysis
Wolf of Value rates Becton, Dickinson and Company (BDX) as a 'BUY' under $160/share, citing attractive fundamentals and a conservative valuation approach despite the company's recent spin-off of its high-margin bioscience segment. The analysis highlights that BDX retains core medical technology operations which maintain solid profitability and robust cash flow generation. The analyst views BDX's current price-to-earnings (P/E) ratio of 13x as undervalued, projecting a fair value target of $215/share by 2028E and estimating an annualized return above 15% at current prices. Although the company meets key quality and safety criteria, the analyst notes that the spin-off has reduced diversification and margin potential, which warrants adopting a conservative 15x P/E multiple for valuation purposes rather than applying higher multiples typically seen in diversified medical technology firms. The author emphasizes an investment strategy focused on cheap, qualitative companies with appealing market share and solid economic moats within the healthcare and healthtech sectors. Wolf of Value, managed by a senior analyst and private portfolio manager with over 10 years of experience, provides this research alongside model portfolios and real-time chat access for its members. The article includes standard financial disclosures stating that the author holds no stock or options in BDX and has no business relationships with the company. It explicitly clarifies that while the content is structured as a value-oriented investment idea, it is not financial advice, and investors are expected to perform their own due diligence. The analyst owns European/Scandinavian tickers for listed companies in those regions and Canadian tickers for Canadian stocks, acknowledging specific withholding tax risks associated with non-US investments. Seeking Alpha's disclosures reiterate that past performance does not guarantee future results and that the views expressed do not necessarily reflect those of the platform as a whole.